Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.

@article{Lehrnbecher2012GuidelineFT,
  title={Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.},
  author={Thomas Lehrnbecher and Robert Phillips and Sarah Alexander and Frank Alvaro and Fabianne Carlesse and Brian T. Fisher and Hana Hakim and Mar{\'i}a E. Santolaya and Elio Castagnola and Bonnie Davis and Lee L. Dupuis and Faith Gibson and Andreas H. Groll and Aditya H. Gaur and Ajay Gupta and Rejin Kebudi and S{\'e}rgio Petrilli and William J. Steinbach and Milena Villarroel and Theoklis Zaoutis and Lillian Sung},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 35},
  pages={
          4427-38
        }
}
  • T. Lehrnbecher, R. Phillips, L. Sung
  • Published 10 December 2012
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To develop an evidence-based guideline for the empiric management of pediatric fever and neutropenia (FN. [] Key Method We followed previously validated procedures for creating evidence-based guidelines. Working groups focused on initial presentation, ongoing management, and empiric antifungal therapy. Each working group developed key clinical questions, conducted systematic reviews of the published literature, and compiled evidence summaries.
View on PubMed
aphon.org
290 Citations
Highly Influential Citations
13
Background Citations
82
Methods Citations
14
Results Citations
7

Tables from this paper

290 Citations

Citation Type

Citation Type

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.
TLDR
Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation and future work should focus on closing research gaps and on identifying ways to facilitate implementation and adaptation.
Communicating safe outpatient management of fever and neutropenia.
TLDR
The ASCO Clinical Practice Guidelines Committee identified outpatient management of febrile neutropenia (FN) as a priority new topic and provides evidence-based recommendations on preventing infection of afebrile adult oncology outpatients with neutropania, and on selection of and initial empiric therapy for individuals with fever and neutropy who can be treated safely in the outpatient setting.
Guidance Statement for the Management of Febrile Neutropenia in Pediatric Patients Receiving Cancer-Directed Therapy in Central America and the Caribbean
TLDR
The panel made recommendations on the basis of existing evidence but identified important gaps in knowledge from the region and from resource-limited settings that may affect the clinical applicability of these recommendations.
Pediatric-specific guidelines for fever and neutropenia: a catalyst for improving care and focusing research.
  • M. Pulsipher
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Lehrnbecher et al, an international panel of experts in infectious disease and pediatric cancer, used well-validated approaches for creating evidence-based guidelines to assemble pediatric-specific recommendations that have filled this major gap.
Management of fever and neutropenia in paediatric cancer patients: room for improvement?
TLDR
A consensus guideline for paediatric fever and neutropenia research is now available and may help reduce some of the heterogeneity between studies that have previously limited the translation of evidence into clinical practice.
Treatment of fever in neutropenia in pediatric oncology patients
TLDR
A number of studies have recently been performed to refine algorithms regarding initiation, modification, and termination of antimicrobial treatment and are the basis for international pediatric-specific guidelines for the treatment of fever and neutropenia in children with cancer.
[Recommendations for Diagnostics and Therapy of Children with Cancer Presenting with Fever and Neutropenia - Comparison of Two Current Guidelines].
Immunocompromised children and adolescents receiving treatment for cancer have a considerably increased risk for infection. Neutropenia is the most important single risk factor for infectious…
Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies.
  • J. Gea-Banacloche
  • Medicine
    Hematology. American Society of Hematology. Education Program
  • 2013
TLDR
Applying the principles of evidence-based medicine to febrile neutropenia results in a more limited set of practices than expected and many practical management questions remain unaddressed.
Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland
TLDR
An Internet-based survey was conducted in 2016 concerning the management of febrile neutropenia in pediatric oncology centers (POC) to document current practice before its implementation in clinical practice.
Pediatric Febrile Neutropenia: Change in Etiology of Bacteremia, Empiric Choice of Therapy and Clinical Outcomes
TLDR
Empiric antibiotic treatment should be tailored to patients’ risk for VGS and multidrug-resistant organisms, and individual hospitals should monitor the pathogens causing FN among patients with cancer to guide choice of empiric therapy.
...
...

References

SHOWING 1-10 OF 153 REFERENCES
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
  • A. Freifeld, E. Bow, J. Wingard
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
TLDR
This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002 and developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, antifungal, and antiviral prophylaxis.
Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection.
TLDR
Combining selected information accessible at presentation, SBI in FN can be predicted with clinically useful specificity maintaining very high sensitivity, aiming at more selective management of FN in pediatric oncology.
Children With Cancer, Fever, and Treatment-Induced Neutropenia: Risk Factors Associated With Illness Requiring the Administration of Critical Care Therapies
TLDR
Pediatric patients with cancer, fever, and treatment-induced neutropenia who present with higher fever or prolonged CFT are at increased risk of developing life-threatening illnesses requiring administration of critical care therapies, independent of hematologic factors, type of cancer, or other physiologic signs of sepsis.
"Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia.
TLDR
Pediatric oncology outpatients with fever and neutropenia who present with an initial monocyte count of >/= 0.1 x 10(9)/L and do not have comorbidity or an abnormal CXR at the time of presentation are at lower risk for SBI and can be considered for less aggressive initial therapy.
Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient.
  • C. Mullen, G. Buchanan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1990
TLDR
"Early" discharge of an afebrile yet still neutropenic patient is suggested to be safe when the patient is in remission, has no evidence of serious infection, appears clinically stable, and has indications of bone marrow recovery.
Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study.
TLDR
For children with cancer as well as episodes of fever and neutropenia without an identifiable bacterial etiology at admission, stopping antibiotic therapy on day 3 was safe and not associated with a higher risk of bacterial superinfections.
Risk Factors Associated With Invasive Fungal Disease in Children With Cancer and Febrile Neutropenia: A Prospective Multicenter Evaluation
TLDR
Fever persisting at day 4 of admission, together with AMC ≤100 and CRP ≥90 significantly increased the risk for IFD in children with cancer.
Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia
TLDR
Clinicians appear to be skilled at selecting children with FN who can safely have IVAMT discontinued before their absolute neutrophil count (ANC) reached 500 /mm3 at the discretion of the clinician.
EPISODES OF FEVER AND NEUTROPENIA IN CHILDREN WITH CANCER IN A TERTIARY CARE MEDICAL CENTER IN TURKEY
TLDR
The aim of this study was to determine the clinical features and microbiological spectrum during episodes of fever and neutropenia in children with cancer and to consider a more selective management strategy for children with these problems.
Empirical antifungal therapy in neutropaenic cancer patients with persistent fever
...
...